Paper32044401
Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate.
Wen WH and 12 others. J Hepatol, 2020. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate. Papers, record 32044401. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32044401
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiviral Agents | Major topic |
| Bone Development | Major topic |
| Hepatitis B virus | Major topic |
| Hepatitis B, Chronic | Major topic |
| Infectious Disease Transmission, Vertical | Major topic |
| Pregnancy Complications, Infectious | Major topic |
| Tenofovir | Major topic |
| Adult | |
| Child | |
| Child, Preschool | |
| DNA, Viral | |
| Female | |
| Follow-Up Studies | |
| Glomerular Filtration Rate | |
| Humans | |
| Kidney | |
| Male | |
| Pregnancy | |
| Prospective Studies | |
| Young Adult |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01312012 | The Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus-drug Test | Derived from the trial | Yes |
Source ClinicalTrials.gov
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42755564 | In utero and lactational exposure to tenofovir disoproxil fumarate and bone health outcomes: a scoping review of 31 studies. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42755564 | PubMed |
| 42328619 | Chinese clinical practice guidelines for the prevention and treatment of mother-to-child transmission of hepatitis B virus (version 2024). | Infect Dis Immun | 2025 | https://conductscience.org/library/papers/42328619 | PubMed |
| 40887644 | Impact of stopping Tenofovir disoproxil fumarate at various times on elevated postpartum ALT levels and breastfeeding in pregnant women with chronic hepatitis B: a prospective observational cohort study. | BMC Pregnancy Childbirth | 2025 | https://conductscience.org/library/papers/40887644 | PubMed |
| 40828798 | Is health, growth and development impaired in children who are Hepatitis B-exposed but uninfected? | PLOS Glob Public Health | 2025 | https://conductscience.org/library/papers/40828798 | PubMed |
| 40790753 | Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D. | Virol J | 2025 | https://conductscience.org/library/papers/40790753 | PubMed |
| 40689368 | Indian National Association for the Study of the Liver Position Statements on Prevention, Diagnosis, and Management of Hepatitis B Virus Infection in India. | J Clin Exp Hepatol | 2025 | https://conductscience.org/library/papers/40689368 | PubMed |
| 39544248 | Chinese Clinical Practice Guidelines for the Prevention and Treatment of Mother-to-child Transmission of Hepatitis B Virus (Version 2024). | J Clin Transl Hepatol | 2024 | https://conductscience.org/library/papers/39544248 | PubMed |
| 39528419 | In-utero exposure to tenofovir-containing pre-exposure prophylaxis and bone mineral content in HIV-unexposed infants in South Africa. | J Int AIDS Soc | 2024 | https://conductscience.org/library/papers/39528419 | PubMed |
| 39267564 | [Chinese practice guidelines for the prevention and treatment of mother-to-child transmission of hepatitis B virus (version 2024)]. | Zhonghua Gan Zang Bing Za Zhi | 2024 | https://conductscience.org/library/papers/39267564 | PubMed |
| 38805690 | Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Preventing Vertical Transmission in Chronic Hepatitis B Mothers: A Systematic Review and Meta-Analysis. | Clin Infect Dis | 2024 | https://conductscience.org/library/papers/38805690 | PubMed |
| 37554925 | Enhancing interventions for prevention of mother-to-child- transmission of hepatitis B virus. | JHEP Rep | 2023 | https://conductscience.org/library/papers/37554925 | PubMed |
| 36304493 | Management Algorithm for Prevention of Mother-to-child Transmission of Hepatitis B Virus (2022). | J Clin Transl Hepatol | 2022 | https://conductscience.org/library/papers/36304493 | PubMed |
| 35113359 | Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy. | Hepatol Int | 2022 | https://conductscience.org/library/papers/35113359 | PubMed |
| 35045168 | Proximal tubular dysfunction in pregnant women receiving tenofovir disoproxil fumarate to prevent mother-to-child transmission of hepatitis B virus. | J Antimicrob Chemother | 2022 | https://conductscience.org/library/papers/35045168 | PubMed |
| 34073357 | Benefits and Risks of Antiviral Treatment during Pregnancy in Patients with Chronic Hepatitis B. | J Clin Med | 2021 | https://conductscience.org/library/papers/34073357 | PubMed |
| 33979956 | [Management algorithm for prevention of mother-to-child transmission of hepatitis B virus (2021)]. | Zhonghua Gan Zang Bing Za Zhi | 2021 | https://conductscience.org/library/papers/33979956 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| TENOFOVIR | CHEMBL3989702 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL3989702 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32044401
GET https://conductscience.org/api/papers/v1/32044401/authors